Oncology
2 drugs are in development for Metastatic Prostate Cancer.
- Companies
- 1
- Clinical trials
- 37
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Metastatic Prostate Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(2)
| Drug | Company |
|---|---|
| oric-533 | Oric Pharmaceuticals, Inc. (ORIC) |
| oric-944 | Oric Pharmaceuticals, Inc. (ORIC) |
About this indication
Metastatic Prostate Cancer context
Oncology·MeSH: Prostatic Neoplasms (D011471)
Narrower concept of MeSH descriptor Prostatic Neoplasms
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Metastatic Prostate Cancer?
BioSniper tracks 2 drugs in development for Metastatic Prostate Cancer across 1 company.
How many clinical trials target Metastatic Prostate Cancer?
There are 37 clinical trials targeting Metastatic Prostate Cancer tracked by BioSniper.
What is the prevalence of Metastatic Prostate Cancer?
The estimated prevalence of Metastatic Prostate Cancer is approximately 256.0 per 100,000 population.